Financials Sansure Biotech Inc.

Equities

688289

CNE1000043J1

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
17.63 ^CNY	-0.23%		-1.29%	-9.82%

Jun. 12	Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification	MT
Apr. 26	Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Valuation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	45,580	23,600	12,747	11,187	10,022	-	-
Enterprise Value (EV) ¹	45,580	23,600	12,747	11,187	10,022	10,022	10,022
P/E ratio	17.4 x	10.5 x	6.63 x	31 x	31.5 x	22.6 x	17.6 x
Yield	-	-	-	-	-	-	-
Capitalization / Revenue	9.56 x	5.23 x	-	11.1 x	6.7 x	4.99 x	4.06 x
EV / Revenue	9.56 x	5.23 x	-	11.1 x	6.7 x	4.99 x	4.06 x
EV / EBITDA	14.6 x	8.83 x	-	-	23.4 x	16.6 x	13 x
EV / FCF	-	-	-	-	-23.2 x	-87.9 x	-181 x
FCF Yield	-	-	-	-	-4.3%	-1.14%	-0.55%
Price to Book	9.62 x	3.71 x	-	-	1.4 x	1.33 x	1.25 x
Nbr of stocks (in thousands)	592,000	592,000	580,726	572,209	568,450	-	-
Reference price ²	76.99	39.86	21.95	19.55	17.63	17.63	17.63
Announcement Date	2/25/21	2/24/22	4/18/23	2/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	365.4	4,767	4,515	-	1,006	1,496	2,009	2,468
EBITDA ¹	-	3,115	2,673	-	-	428	603	768
EBIT ¹	-	3,085	2,622	-	-	387	548	687
Operating Margin	-	64.72%	58.07%	-	-	25.87%	27.28%	27.84%
Earnings before Tax (EBT) ¹	-	3,069	2,616	-	-	382	533	675
Net income ¹	-	2,616	2,243	1,937	360.2	329	458	586
Net margin	-	54.87%	49.68%	-	35.79%	21.99%	22.8%	23.74%
EPS ²	0.0743	4.419	3.791	3.310	0.6300	0.5600	0.7800	1.000
Free Cash Flow ¹	-	-	-	-	-	-431.3	-114	-55.25
FCF margin	-	-	-	-	-	-28.83%	-5.67%	-2.24%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	8/9/20	2/25/21	2/24/22	4/18/23	2/28/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q3
Net sales	-
EBITDA	-
EBIT	-
Operating Margin	-
Earnings before Tax (EBT)	-
Net income ¹	208
Net margin	-
EPS ²	0.3500
Dividend per Share	-
Announcement Date	10/30/23

¹CNY in Million²CNY

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-	-	-431	-114	-55.3
ROE (net income / shareholders' equity)	-	107%	39%	-	-	4.4%	5.9%	7.1%
ROA (Net income/ Total Assets)	-	85.8%	-	-	-	3.9%	5.1%	6.3%
Assets ¹	-	3,048	-	-	-	8,436	8,980	9,302
Book Value Per Share ²	-	8.010	10.80	-	-	12.60	13.30	14.10
Cash Flow per Share	-	4.460	3.170	-	-	-	-	-
Capex ¹	-	-	-	-	-	340	245	250
Capex / Sales	-	-	-	-	-	22.72%	12.2%	10.12%
Announcement Date	8/9/20	2/25/21	2/24/22	4/18/23	2/28/24	-	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Sansure Biotech Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.63 CNY

Average target price

25 CNY

Spread / Average Target

+41.80%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
SANSURE BIOTECH INC.	-9.82%	1.38B
BIOMÉRIEUX	-4.72%	12.35B
LANTHEUS HOLDINGS, INC.	+99.06%	8.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.10%	6.6B
DIASORIN S.P.A.	+8.48%	5.88B
AUTOBIO DIAGNOSTICS CO., LTD.	-22.96%	3.52B
ANDON HEALTH CO., LTD.	+6.08%	2.55B
MYRIAD GENETICS, INC.	+38.04%	2.39B
VITROLIFE AB	-7.04%	2.33B
10X GENOMICS, INC.	-68.75%	2.09B

Diagnostic & Testing Substances